Participant Flow Module
The Participant Flow Module provides information about the flow of participants through each stage of the clinical trial. This includes pre-assignment details, recruitment information, and the types of units analyzed, helping researchers understand how participants move through the study.
Participant Flow Module path is as follows:
Study -> Results Section -> Participant Flow Module
Participant Flow Module
Ignite Creation Date:
2025-12-24 @ 1:59 PM
Ignite Modification Date:
2025-12-25 @ 12:45 PM
NCT ID:
NCT03192995
Pre Assignment Details:
On 2/13/2020, the Food and Drug Administration (FDA) issued a safety alert after concluding the assessment of the long-term safety of lorcaserin in CAMELLIA clinical trial among 6,000 participants who took lorcaserin for over 4.3 years and were overweight or obese, with cardiovascular disease. The analysis showed an increased risk of cancer. In response to the safety alert, active participants in our study were instructed to stop study medication use and informed of the FDA safety alert.
Study:
NCT03192995
Study Brief:
Results Section:
NCT03192995